Kura Oncology to Announce Q3 2024 Financial Results

SAN DIEGO, Oct. 31, 2024 - Kura Oncology, Inc. (Nasdaq: KURA), a company in the clinical-stage of biopharmaceutical development focused on precision medicines for cancer treatment, has announced it will release its financial results for the third quarter of 2024 after the U.S. financial markets close on Thursday, November 7, 2024. A webcast and conference call will be hosted by Kura’s management on the same day at 4:30 p.m. ET / 1:30 p.m. PT to discuss these results and provide a corporate update. Those interested can join the call by dialing (800) 225-9448 for domestic callers or (203) 518-9708 for international callers, using the conference ID: KURAQ3. A live webcast and an archived replay will be accessible via the company’s website in the investor relations section.

Kura Oncology is a biopharmaceutical firm at the clinical stage, dedicated to developing precision medicines for treating cancer. Their pipeline includes small molecule drug candidates that target cancer signaling pathways. One of their prominent drug candidates is Ziftomenib, an oral medication taken once daily, which targets the interaction between the menin-KMT2A proteins. Ziftomenib has been granted Breakthrough Therapy Designation for treating relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The company has completed patient enrollment in a Phase 2 registration-directed trial of Ziftomenib for R/R NPM1-mutant AML, named KOMET-001. Additionally, Kura is conducting various clinical trials to assess the effectiveness of Ziftomenib in combination with standard care treatments for newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML.

Another drug in Kura’s pipeline is KO-2806, a next-generation farnesyl transferase inhibitor (FTI) currently being evaluated in a Phase 1 dose-escalation trial as a standalone therapy and in combination with other targeted treatments (FIT-001). Additionally, Tipifarnib, a potent and selective FTI, is undergoing a Phase 1/2 trial in combination with alpelisib for patients suffering from PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN).
 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!